Taysha Gene Therapies (TSHA) Expected to Announce Quarterly Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) will likely be announcing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $0.7560 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million during the quarter, compared to the consensus estimate of $1.89 million. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA traded up $0.28 during midday trading on Monday, reaching $6.61. 831,135 shares of the company’s stock were exchanged, compared to its average volume of 2,739,407. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. The company’s 50 day simple moving average is $4.95 and its two-hundred day simple moving average is $4.89. Taysha Gene Therapies has a 12 month low of $1.85 and a 12 month high of $6.76. The firm has a market capitalization of $1.90 billion, a PE ratio of -19.43 and a beta of 1.25.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TSHA. Raymond James Financial reiterated a “strong-buy” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Chardan Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Wall Street Zen raised Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, April 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and an average target price of $11.64.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider owned 1,136,410 shares in the company, valued at $5,068,388.60. The trade was a 14.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by company insiders.

Institutional Trading of Taysha Gene Therapies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. lifted its position in shares of Taysha Gene Therapies by 376.3% in the fourth quarter. Invesco Ltd. now owns 1,332,780 shares of the company’s stock valued at $7,330,000 after buying an additional 1,052,987 shares during the last quarter. Oracle Investment Management Inc. bought a new stake in Taysha Gene Therapies in the 4th quarter valued at $1,458,000. Voloridge Investment Management LLC acquired a new stake in Taysha Gene Therapies during the 4th quarter valued at $301,000. Vestal Point Capital LP lifted its holdings in Taysha Gene Therapies by 150.0% during the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after purchasing an additional 8,250,000 shares during the last quarter. Finally, Virtus Investment Advisers LLC boosted its position in Taysha Gene Therapies by 7.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock worth $253,000 after purchasing an additional 3,008 shares during the period. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.